GLP-1 coverage by state

Whether Medicaid will pay for a GLP-1 depends on which state you live in, and in 2025-26 several states changed their answer. This is the national picture, and the states where something specific happened.

Coverage of GLP-1s for obesity is optional for state Medicaid programmes. As of January 2026, 13 covered them under fee-for-service — down from 16 in October 2025. Source: KFF, “Medicaid Coverage of and Spending on GLP-1s”, 16 January 2026.

States where Medicaid does cover GLP-1s for obesity

Michigan, Tennessee, Virginia, Minnesota, Wisconsin, Missouri, Kansas, Delaware all cover GLP-1s for obesity treatment, alongside Mississippi and Utah. If you are in one of these states and on Medicaid, that is almost certainly a better route than anything you can buy for cash — enrollees generally pay little or no copay for prescription drugs.

Two caveats. Coverage is typically subject to prior authorisation, and at least one covering state — Michigan — has narrowed eligibility to morbid obesity rather than eliminating coverage, a move expected to save it around $240 million. Coverage existing is not the same as you qualifying.

States where coverage has been proposed for removal

Massachusetts and Rhode Island both had live proposals to end Medicaid coverage of GLP-1s for weight loss as of April 2026. Neither had taken effect at the time of reporting. If you are eligible in either state, the sensible read is that the window may not stay open.

States that eliminated coverage

California, Pennsylvania, South Carolina, New Hampshire all ended coverage of GLP-1s for obesity after October 2025, which KFF attributes to budget pressure and drug cost.

States that changed course

North Carolina dropped coverage in October 2025 during a budget stalemate and reinstated it that December — the change that brought the national total back to 13.

States covering weight-loss drugs but no GLP-1s

Texas, Louisiana, Connecticut, New Mexico, North Dakota report covering one or more weight-loss drugs while covering no GLP-1 at all. It is the distinction that catches most people out, because a weight-loss benefit on paper reads like a yes.

Time-limited coverage

Utah reported that funding for coverage was limited to fiscal year 2026 — a deadline rather than a refusal.

The states at the extremes

West Virginia, Mississippi, Colorado stand out on prevalence rather than policy. Every US state and territory recorded adult obesity prevalence of at least 25% in 2024.

Among adults aged 40-59 — the age band most of our readers fall into — 43 states and 3 territories recorded prevalence of 35% or higher. Source: CDC Adult Obesity Prevalence Maps, 2024 data, published 3 December 2025.

If your state is not listed above

Then we have nothing state-specific and verifiable to tell you, and we would rather say so than pad this out. Every provider we track is 50-state telehealth charging the same price wherever you live, so there is no local market to report. What to do instead: ring your plan and ask about the specific medication by name.

Medicare, which does not vary by state

From 1 July 2026 through 31 December 2027, CMS is running a demonstration giving eligible Part D beneficiaries certain GLP-1s for $50 a month. See the Medicare briefing.

Paying cash, wherever you are